Purpose: To explore symptoms and disease impacts of Crohn’s disease and to develop a new patient-reported outcomes (PRO) measure according to industry best practices. Methods: A conceptual model of relevant symptoms experienced by patients with Crohn’s disease was developed following a literature review. Three rounds of combined qualitative semi-structured concept elicitation and cognitive debriefing interviews with 36 patients (≥ 16 years) with Crohn’s disease and 4 clinicians were conducted to further explore the most commonly reported and most bothersome symptoms to patients. Interview results were used to update the conceptual model as well as items and response options included in The Crohn’s Disease Diary, a new PRO measure. Results: All patients (N = 36) reported abdominal pain, loose or liquid bowel movements, and high or increased frequency of bowel movements, with most reporting these symptoms spontaneously (100%, 92%, and 75%, respectively). All patients reported bowel movement urgency, but 61% reported this symptom only when probed. Most also reported that symptoms impacted activities of daily living, work/school, and emotional, social, and physical functioning (overall, 78%–100%; spontaneously, 79% – 92%). Data regarding core symptoms of Crohn’s disease from clinician concept elicitation interviews supported patient data. The 17-item Crohn’s Disease Diary assesses core symptoms and impacts of Crohn’s disease over 24 h, and extraintestinal manifestations over 7 days. The content validity of the diary was confirmed during cognitive debriefing interviews. Conclusion: The Crohn’s Disease Diary is a new PRO measure for the assessment of Crohn’s disease symptoms and impacts, developed according to industry best practices.
Introduction Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) are patient-reported outcome (PRO) instruments assessing Sjögren’s symptoms. Original SSSD items have demonstrated content validity, however qualitative evidence supporting the updated ‘tiredness’ item and two new supplementary items is lacking. Although well established and validated in other rheumatic diseases, there is no qualitative evidence supporting content validity of FACIT-F in Sjögren’s. This study addressed these evidence gaps to support use of SSSD and FACIT-F as clinical trial endpoints, in clinical practice and in other research settings. Methods Qualitative, semi-structured telephone interviews were conducted with patients with Sjögren’s (n = 12) and expert Sjögren’s physicians (n = 10). Patient interviews explored content validity (e.g., understanding and relevance) of the new and updated SSSD items, perceptions of item and total score meaningful change on SSSD, and understanding and relevance of FACIT-F items. Physician interviews explored opinions on various SSSD scoring approaches. Results The new and updated SSSD items and FACIT-F demonstrated good content validity. Most patients considered a two-point improvement on most SSSD items meaningful, as well as a one- or two-point total score improvement. Most physicians reported tracking changes in patient responses to individual items as the most appropriate SSSD scoring approach. Conclusions SSSD and FACIT-F are content valid in a Sjögren’s population, meeting an important criterion to support their use as clinical trial endpoints, but also their use in clinical practice and other research settings. Qualitative data exploring meaningful change will be valuable in supporting psychometrically derived responder definitions.
Background: The 5-item Asthma Control Questionnaire (ACQ-5) is widely used in clinical trials to assess the adequacy of asthma symptom control and any changes in asthma control as a result of treatment. Evidence supporting the psychometric properties of the ACQ-5, including a 0.5-threshold for meaningful improvement, was derived using methods that are no longer recommended in the literature or by regulatory authorities. The primary objective of this research was to derive meaningful change estimates using contemporary methods to evaluate clinically important change for the ACQ-5. A secondary objective was to evaluate the applicability of the existing ACQ-5 asthma control threshold for defining “well-controlled” asthma (ACQ-5 ≤ 0.75). Methods: Measurement properties (item performance, reliability, validity, and responsiveness) were assessed prior to evaluating meaningful change, using data from a sample of 196 adults with inadequately controlled moderate-to-severe asthma from a placebo-controlled, Phase 2 study of rilzabrutinib (NCT05104892). Anchor- and distribution-based analyses were used to derive meaningful within-patient change (MWPC) and meaningful between-group difference (MBGD). Applicability of the existing ACQ-5 asthma control threshold was evaluated by plotting the positive predictive value (PPV) and negative predictive value (NPV) of the ACQ-5 total score in the current study against the PPV and NPV calculated in the original Juniper et al. (2006) study. Results: High internal consistency (Cronbach’s alpha = 0.90), moderate-to-strong convergent validity (r range: 0.52–0.83), and ability to detect improvements in asthma control based on psychometric and physiological measures were demonstrated for the ACQ-5. Test-retest reliability results were poor-to-moderate (intraclass correlation coefficient range: 0.30–0.66). Of the anchor-based estimates derived (0.2 to 1.6), empirical cumulative distribution function plots supported 0.6 or 0.8 as appropriate MWPC thresholds. Estimated MBGD ranged from 0.2 to 0.6. PPV/NPV plots supported continued use of a 0.75- threshold to determine “well-controlled” asthma. Conclusion: Contemporary score interpretation methods support a MWPC threshold of ≥ 0.6, which is functionally identical to the extant threshold of ≥ 0.5, given the 0.2 increments of the ACQ-5 scale. MBGD ranged from 0.2 to 0.6, further supporting use of the established ≥ 0.5 threshold to define clinically important change between groups of patients. A “well-controlled” threshold of ≤ 0.75 was also supported.
17 October 2026 in Advances in Patient-Reported Outcomes
Aim: To investigate use of the ‘Managing Advanced Cancer Pain Together’ conversation tool between individuals with advanced cancer and healthcare professionals (HCPs) during routine consultations. ... Lay abstract The Managing Advanced Cancer Pain Together conversation tool was designed to help patients with advanced cancer and their healthcare professionals (HCPs) discuss various aspects of pai...